Giuseppe Toffoli


Affiliation: Centro di Riferimento Oncologico
Country: Italy


  1. request reprint
    Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A. Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. Int J Biol Markers. 2003;18:218-21 pubmed
    ..These results indicate that MTHFR variants are not related to DLBCL development and MGMT hypermethylation...
  2. Gagno S, D Andrea M, Mansutti M, Zanusso C, Puglisi F, Dreussi E, et al. A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. Clin Breast Cancer. 2019;19:137-145.e4 pubmed publisher
    ..012), respectively. In this study we defined a score including 5 polymorphisms to stratify patients for PFS and OS. This score, if validated, might be translated to personalize locally advanced or MBC patient treatment and management. ..
  3. request reprint
    Toffoli G, Gafa R, Russo A, Lanza G, Dolcetti R, Sartor F, et al. Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy. Clin Cancer Res. 2003;9:743-8 pubmed
    ..01; 95% confidence interval, 0.48-2.14). Our findings support a role for MTHFR 677 TT genotype in reducing proximal CLC risk in North Italy. ..
  4. Cecchin E, De Mattia E, Ecca F, Toffoli G. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Drug Resist Updat. 2018;39:18-40 pubmed publisher
    ..Available pharmacogenomics guidelines with ongoing efforts to implement them in clinical practice and new exploratory markers for clinical validation are described. ..
  5. Garziera M, Cecchin E, Canzonieri V, Sorio R, Giorda G, Scalone S, et al. Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). Int J Mol Sci. 2018;19: pubmed publisher
    ..This discovery of previously unreported TP53 somatic mutations provides an opportunity to translate NGS technology into personalized medicine and identify new potential targets for therapeutic applications. ..
  6. Traldi P, Calandra E, Crotti S, Agostini M, Nitti D, Roverso M, et al. Matrix-assisted laser desorption/ionization, nanostructure-assisted laser desorption/ionization and carbon nanohorns in the detection of antineoplastic drugs. 1. The cases of irinotecan, sunitinib and 6-alpha-hydroxy paclitaxel. Eur J Mass Spectrom (Chichester). 2014;20:445-59 pubmed publisher
    ..The analysis of plasma samples spiked with 1 showed, again, that the MALDI approach was the best one (R(2) = 0.9766). The failure of NALDI measurements could be rationalized by the presence of ion suppression effects. ..
  7. request reprint
    Toffoli G, Corona G, Cattarossi G, Boiocchi M, Di Gennaro G, Tirelli U, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol. 2004;15:1805-9 pubmed
    ..Other factors beside DOX plasma levels are detrimental for toxicity after CHOP + HAART. Therefore, pharmacodynamic interactions between HAART and DOX should be considered. ..
  8. request reprint
    Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, et al. Effect of methylenetetrahydrofolate reductase 677C-->T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer. 2003;103:294-9 pubmed
    ..0004). In conclusion, our data suggest that the TT MTHFR 677 genotype is associated with marked MTX-induced hyperhomocysteinemia and could represent a pharmacogenetic marker for toxicity after chronic treatment with low doses of MTX. ..
  9. De Mattia E, Cecchin E, Toffoli G. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Drug Resist Updat. 2015;20:39-70 pubmed publisher

More Information


  1. Farra R, Musiani F, Perrone F, Cemazar M, Kamensek U, Tonon F, et al. Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness. Molecules. 2018;23: pubmed publisher
    ..Attention will be also put on the mathematical description of the mechanisms ruling siRNA-carrier delivery, this being an important aspect to improve effectiveness reducing the experimental work. ..
  2. Dreussi E, Cecchin E, Polesel J, Canzonieri V, Agostini M, Boso C, et al. Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. Int J Mol Sci. 2016;17: pubmed publisher
    ..073). This exploratory study highlighted new potential predictive biomarkers of neoadjuvant CRT and underlined the importance to strictly define treatment peculiarities in pharmacogenetic analyses. ..
  3. Pellizzoni E, Tommasini M, Marangon E, Rizzolio F, Saito G, Benedetti F, et al. Fluorescent molecularly imprinted nanogels for the detection of anticancer drugs in human plasma. Biosens Bioelectron. 2016;86:913-919 pubmed publisher
    ..The LOD was 400nM, with within-run variability <9%, day to day variability <5%, and good accuracy in the recovery of sunitinib from spiked samples. ..
  4. Giodini L, Re F, Campagnol D, Marangon E, Posocco B, Dreussi E, et al. Nanocarriers in cancer clinical practice: a pharmacokinetic issue. Nanomedicine. 2017;13:583-599 pubmed publisher
  5. Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, Polesel J, et al. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. Int J Mol Sci. 2017;18: pubmed publisher
    ..This exploratory study identified new HLA-G 3'UTR polymorphisms/haplotypes as potential predictive markers of G3-4 toxicities in CRC. ..
  6. request reprint
    Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-8 pubmed
    ..In particular, the possibility of a dose reduction for irinotecan in patients with a UGT1A1*28 polymorphism is not supported by the result of this analysis. ..
  7. Toffoli G, Cecchin E, Gasparini G, D Andrea M, Azzarello G, Basso U, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:866-71 pubmed publisher
    ..Prospective genotype-driven studies should test the efficacy of higher irinotecan doses in the FOLFIRI schedule. ..
  8. Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger C, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15:3550-6 pubmed publisher
    ..17-6.11). The study provides evidence supporting the association of MDM2 SNP309 with high-grade osteosarcoma risk in females and shows that TP53 Arg72Pro has a prognostic value for overall survival and EFS in osteosarcoma patients. ..
  9. Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G. Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. Int J Mol Sci. 2017;18: pubmed publisher
  10. Guida F, Battisti A, Gladich I, Buzzo M, Marangon E, Giodini L, et al. Peptide biosensors for anticancer drugs: Design in silico to work in denaturizing environment. Biosens Bioelectron. 2018;100:298-303 pubmed publisher
    ..These results suggest that the in silico design of small artificial peptides is now a viable route for designing sensing units, opening a wide range of applications in diagnostic and clinical areas. ..
  11. De Mattia E, Cecchin E, Polesel J, Bignucolo A, Roncato R, Lupo F, et al. Genetic biomarkers for hepatocellular cancer risk in a caucasian population. World J Gastroenterol. 2017;23:6674-6684 pubmed publisher
    ..We identified five polymorphisms and interactions that contributed crucially to predicting HCC risk. These findings represented an important step towards improving HCC diagnosis and management. ..
  12. request reprint
    Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G. Pharmacology of epidermal growth factor inhibitors. Int J Biol Markers. 2007;22:S24-39 pubmed